Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives by Matesic, Lidia et al.
University of Wollongong 
Research Online 
Faculty of Science - Papers (Archive) Faculty of Science, Medicine and Health 
1-1-2012 
Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, 
pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives 
Lidia Matesic 
University of Wollongong, lidiam@uow.edu.au 
Julie M. Locke 
University of Wollongong, jlocke@uow.edu.au 
Kara Vine 
University of Wollongong, kara@uow.edu.au 
Marie Ranson 
University of Wollongong, mranson@uow.edu.au 
John B. Bremner 
University of Wollongong, jbremner@uow.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/scipapers 
 Part of the Life Sciences Commons, Physical Sciences and Mathematics Commons, and the Social 
and Behavioral Sciences Commons 
Recommended Citation 
Matesic, Lidia; Locke, Julie M.; Vine, Kara; Ranson, Marie; Bremner, John B.; and Skropeta, Danielle: 
Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, 
pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives 2012, 6810-6819. 
https://ro.uow.edu.au/scipapers/4743 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, 
pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives 
Abstract 
To further expand the structure–cytotoxic activity relationships of isatin derivatives and to reduce 
flexibility in substituent groups at nitrogen, 20 analogues incorporating a ring system between the N1 and 
C7 atoms of isatin were prepared using a variety of synthetic strategies. This yielded pyrroloindole-, 
pyrroloquinoline-, pyrroloacridine-, pyrrolophenanthridine- and benzopyrrolophenanthridine-based systems 
with embedded isatin moieties, the latter possessing a novel carbon skeleton. These compounds were 
subsequently assessed for their in vitro cytotoxicity against human U937 lymphoma cells, with the 
brominated pyrroloacridine dione 27 showing the most promising activity (IC50 3.01 μM) after 24 h. 
Keywords 
pyrrolo, derivatives, isatin, polycyclic, other, quinoline, ij, diones, 3, indole, 2, hi, 1, synthesis, anti, 
leukaemic, activity, CMMB 
Disciplines 
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences 
Publication Details 
Matesic, L., Locke, J. M.., Vine, K., Ranson, M., Bremner, J. B. & Skropeta, D. (2012). Synthesis and anti-
leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other 
polycyclic isatin derivatives. Tetrahedron, 68 (34), 6810-6819. 
Authors 
Lidia Matesic, Julie M. Locke, Kara Vine, Marie Ranson, John B. Bremner, and Danielle Skropeta 




Synthesis and anti-leukemic activity of pyrrolo[3,2,1-hi]indole-1,2-diones, 
pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives  
Lidia Matesica, Julie M. Lockeb, Kara L. Vinec, Marie Ransonc, John B. Bremnera and Danielle Skropetaa, 
aSchool of Chemistry and Centre for Medicinal Chemistry, University of Wollongong, Wollongong NSW 2522, Australia 
bIntelligent Polymer Research Institute, University of Wollongong, Wollongong NSW 2522, Australia 
cSchool of Biological Sciences, Centre for Medical Biosciences and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong 
NSW 2522, Australia 
 
——— 
 Corresponding author. Tel.: +61-2-42214360; fax: +61-2-42214287; e-mail: skropeta@uowmail.edu.au 
1. Introduction 
Isatin has been derivatised at the N1, C2, C3, C5, C6 
and C7 positions in an attempt to increase its biological activity, 
in particular its cytotoxicity.1 N-Substituted arylalkyl isatin 
derivatives of type I (Fig. 1) showed excellent potency but it was 
thought that restraining conformational mobility in the 
substituent would further improve activities in these isatins, 
based on improvements in the activity of other anti-cancer agents 
through conformational restrictions.2 In order to achieve this, we 
initially considered target systems with a 5- or 6-membered ring 
present involving N1 and C7 in the isatin (systems of type II or 
III respectively; Fig. 1). In these systems the bromo substituent 
would be replaced by a similarly hydrophobic methylene or 
methine group and rotation about the N-αC bond would be 
restricted. Systems of type II and III correspond to 
pyrrolo[3,2,1-hi]indole-1,2-dione (6,5,5-tricyclic) and 
pyrrolo[3,2,1-ij]quinoline-1,2-dione (6,5,6-tricyclic) derivatives 
respectively. To facilitate comparison between previously 
reported N-alkylisatins1c and the new tricyclic isatins, a bromo 
substituent (R) was to be incorporated to improve cytotoxicity,1b, 
3 and R1 was to be H, alkyl, or aryl. Later target systems 
envisaged incorporating elements of the aryl groups in I in 
further fused rings to afford targets IV(pyrrolo[3,2,1-de]acridine-






































Fig. 2. Further ring fused target systems with an embedded isatin unit. 
 
While the pyrrolo[3,2,1-hi]indole scaffold is well 
known in the scientific literature, there are only three currently 
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known examples of pyrrolo[3,2,1-hi]indole-1,2-diones.4 This 
may be attributed to the fact that 6,5,5-fused indole ring systems 
are highly strained.5 Similarly, the pyrrolo[3,2,1-ij]quinoline 
nucleus is established6 and many compounds containing this 
scaffold have also been reported to exhibit a broad spectrum of 
biological activities including analgesic, anti-pyretic, anti-
inflammatory,6a anti-hyperlipidemic, anti-hypertensive,7 
anti-epileptic, anti-obesity8 and anti-cancer9 activities. 
Approximately 50 of the analogous isatin-based 
pyrrolo[3,2,1-ij]quinoline-1,2-diones have been reported in the 
literature to date. Structures of type IV10 and the ABCDE ring 
system in type V11 are rare in the literature, while the ABCDF 
ring system in type V represents a new heterocyclic scaffold. The 
ABCD ring system in type V is well known, however, and is 
present in many natural products including the Amaryllidaceae 
alkaloids.6a, 12 
Two general approaches were considered for accessing 
the target systems. The first of these (route (i)) was based on 
constructing the 5-membered dione ring B from an amine 
precursor while the second (route (ii)), involved C7-N annulation 
from an isatin precursor (Fig. 3). The outcomes from these two 
approaches, along with the cytotoxic evaluation of the products, 









Fig. 3. General synthetic strategies to the target systems II-V. 
 
2. Results and discussion 
2.1. Pyrroloindole-dione derivatives II 
The Stolle isatin synthesis (route (i), Fig. 3), which 
involves a crucial intramolecular Friedel-Crafts acylation in the 
penultimate ring forming step, was attempted to access these 
derivatives with a 5-membered ring fusion. This synthetic 
approach has been employed to prepare a variety of isatins13 
including N-aryl and polycyclic isatins.14 In 1979, Welstead Jr. et 
al. reported the first synthesis of the tricyclic isatin 2 from 
indoline (1) in 8% overall yield using the Stolle procedure.4a The 
yield was reportedly increased to 22% in 1996 by Norman et al.15 
In the current work, our attempts to synthesise 
pyrrolo[3,2,1-hi]indole-1,2-diones using free radical cyclisations 
and assorted heteroannulations were unsuccessful, however, the 
synthetic method based on the work by Norman et al. provided 
the desired tricyclic isatin 2, albeit in low yield (Scheme 1). 
Subsequent bromination of 2 proceeded smoothly to afford 3 in 
moderate yield. Because of difficulties encountered in the 
cyclisation step, the synthesis of ring C-substituted pyrrolo[3,2,1-
hi]indole-1,2-diones was not pursued. Semi-empirical level 
computational studies (AM1; Materials Studio 4.4) on 2 and its 
analogue with a C4-C5 double bond confirmed the expected 
significant strain in these compounds with positive heats of 
formation values (ΔHf 10.9 and 43.2 kcal/mol respectively). 
2.2. Pyrroloquinoline-dione derivatives III 
2.2.1 Via route(i) 
Pyrrolo[3,2,1-ij]quinoline-1,2-dione (5) was prepared 
by cyclising 1,2,3,4-tetrahydroquinoline (4) following a similar 
method described for the 5-membered analogue 2. The 
compound was subsequently brominated to afford 6 in high yield 




Scheme 1. (a) n = 0: (COCl)2, DCM, RT, 3 h; n = 1: (COCl)2, THF, reflux, 
3 h; (b) n = 0: AlCl3, 110 ºC, 20 min, 15% (over 2 steps); n = 1: AlCl3, DCM, 
reflux, 3 h, 31% (over 2 steps); (c) Br2, 95% EtOH, 70-75 ºC, 3 = 33%; 
6 = 78%. 
 
To further investigate the cytotoxic SAR of the 
6,5,6-fused tricyclic isatins, structures incorporating N-arylalkyl 
substituents were desired. The selective addition of an aryl 
substituent to the cyclised isatin 5 was expected to be difficult, 
hence, the required N-arylalkyl moiety would need to be 
incorporated into the structure prior to cyclisation. Reacting 
quinoline (7), with phenylmagnesium bromide (PhMgBr) formed 
2-phenyl-1,2-dihydroquinoline (8) (Scheme 2). Due to the 
air-sensitivity and instability of 1,2-dihydroquinolines,16 8 was 
used in further reactions immediately after its preparation and 
purification was not attempted. Upon treatment with oxalyl 
chloride and AlCl3, 8 was cyclised to form the novel tricyclic 
isatin 9 in trace amounts, which may be explained in part by the 
use of crude 2-phenyl-1,2-dihydroquinoline (8). The structure of 
9 was confirmed through the 13C NMR spectrum, which 
displayed two diagnostic carbonyl signals at 157.4 and 
182.4 ppm, indicative of C2 and C1 respectively. Due to the low 
yield of 9 and the likelihood of bromine preferentially attacking 
the alkene rather than the aromatic ring, synthesis of the 8-bromo 
analogue was not attempted. 
To prepare the saturated analogue of tricyclic isatin 9, the 
dihydroquinoline 8 was reduced to 2-phenyl-1,2,3,4-
tetrahydroquinoline (10), followed by treatment with oxalyl 
chloride and AlCl3 to afford the tricyclic isatin 11 (Scheme 2), 
which was also indicated by the appearance of two carbonyl 
signals at 156.8 and 183.6 ppm in the 13C NMR spectrum. The 
multiplicities and chemical shifts ascribed to the aromatic protons 
in the 1H NMR spectrum also pointed to cyclisation having 
occurred to the activated C8 position in the tetrahydroquinoline 
nucleus rather than to the ortho-position in the pendant phenyl 
group. The tricyclic isatin 11 was then exposed to Br2 to yield the 























Scheme 2. (a) 1 M PhMgBr, THF, reflux, 18 h, 90% (crude); (b) (COCl)2, 
THF, reflux, 3.5 h; (c) AlCl3, CHCl3, reflux, 18 h, 9 = 1% (over 2 steps); 
10 = 5% (over 2 steps); (d) Na, EtOH, reflux, 2 h, 70%; (e) Br2, 95% EtOH, 
70-75 ºC, 50%. 
 
2.2.2 Via route (ii) 
Many intramolecular Heck reactions have previously 
been applied to indoles to form tricyclic indoles.5, 17 The 
formation of a 1,7-annulated isatin with an eight-membered ring 
through an intramolecular Heck reaction has also been reported,18 
however, the reaction has not been used to form 1,7-annulated 
isatins containing smaller ring sizes. Subjection of N-allyl-7-
bromoisatin (13) to Heck conditions similar to those reported by 
Black et al.5 provided the isomeric 6-endo-trig products 14 and 
15 in a 3:1 ratio (Scheme 3). These products could be isolated by 
preparative TLC.  
To obtain the 8-bromo analogues of 14 and 15 for 
cytotoxicity testing, N-allyl-5,7-dibromoisatin (16) was 
synthesised using the same conditions as for 13. Subsequent 
exposure of 16 to intramolecular Heck conditions gave the 
brominated tricyclic isatins 17 and 18 in moderate yield (Scheme 
3). Analysis by 1H NMR spectroscopy revealed the 4H and 6H 
isomers (17 and 18) had formed in a 3:2 ratio, with the 4H isomer 




Scheme 3. TBACl, K2CO3, Pd(OAc)2, DMF, 85 ºC, 2 h, 14 = 39%; 
15 = 13%; 17 = 29%; 18 = 20%.  
 
The Heck reaction was also applied to other N-allylated 
isatins to further explore the synthesis and cytotoxicity of 
6,5,6-tricyclics with phenyl or methyl substituents in ring C 
(Scheme 4). Thus, 7-bromoisatin (19) was reacted with crotyl 
bromide to yield 20, followed by an intramolecular Heck reaction 
to yield the tricyclic isatin 21, which was formed exclusively as 
determined by 1D and 2D NMR spectroscopy. Due to the low 
yield of 21, synthesis of the analogous 8-bromo analogue was not 
attempted. 7-Bromoisatin (19) was also reacted with cinnamyl 
bromide to provide 22 and a subsequent intramolecular Heck 
reaction gave 23 (Scheme 4).  
 
 
Scheme 4. (a) NaH, DMF, RT, 20 min; (b) crotyl or cinnamyl bromide, KI, 
60 ºC, 18 h, 20 = 59% (over 2 steps); 22 = 97% (over 2 steps); (c) TBACl, 
K2CO3, Pd(OAc)2, DMF, 85 ºC, 2 h, 21 = 8%; 23 = 17%. 
 
2.3.  Pyrroloacridine-, pyrrolophenanthridine- and 
benzopyrrolophenanthridine-dione derivatives IV-V 
In order to further explore the utility of the isatin scaffold 
for the development of novel cytotoxins and to incorporate the 
N-benzylic substituent moiety into a fused aromatic ring, it was 
decided to extend the quinoline nucleus to systems containing 
benzo or naphtho rings fused onto the heterocyclic ring of 
quinoline (Fig. 2). Specific targets included pyrroloacridine-
diones 26 and 27, which incorporated the cytotoxic acridine19 and 
isatin moieties, as well as the pyrrolophenanthridine-diones 30 
and 31 together with the benzopyrrolophenanthridine-dione 
derivative 36, and the isomeric systems in 40 and 41.  
One compact route to the acridine- and phenanthridine-
based isatins applies the Stolle isatin method (route (i), Fig. 3) to 
dihydroacridine 25 and dihydrophenanthridine 29, which can be 
readily accessed in turn from acridine 24 or phenanthridrine 28 
respectively, by reduction20 with NaCNBH3 (Scheme 5). It has 
been shown that the addition of a base and 
4-(dimethylamino)pyridine (DMAP) to 29 was necessary to 
achieve good yields of amide derivatives.21 In this case, the 
addition of N,N-diisopropylethylamine (DIPEA) and a catalytic 
amount of DMAP was employed to facilitate the formation of the 
oxamide intermediate, before being cyclised directly with AlCl3 
to yield 30. The acridine-based isatin 26 was able to be prepared 
without the addition of DIPEA and DMAP in the intermediate 
amide formation step. Bromination of 26 and 30 proceeded 
smoothly in glacial AcOH to yield 27 and 31 (Scheme 5). The 
1H NMR spectrum revealed the absence of the H4 and H2 







Scheme 5. (a) AcOH, EtOH, reflux, 30 min; (b) NaCNBH3, reflux, 1.5 h, 
25 = 47% (over 2 steps); 29 = 77% (over 2 steps); (c) 26 = (COCl)2, THF, 
reflux, 3.5 h; 30 = (COCl)2, DMAP, DIPEA, THF, reflux, 3.5 h; (d) AlCl3, 
CHCl3, reflux, 1.5 h, 26 = 30 = 15% (over 2 steps); (e) Br2, AcOH, 70-75 ºC, 
27 = 41%, 31 = 69%. 
 
An alternative approach (route (ii), Fig. 3) which 
incorporated Pd-mediated intramolecular cyclisation6a  was used 
to prepare the other benzo-fused pyrrolophenanthridine targets. 
These phenanthridine-embedded isatins could be prepared 
through the Pd-catalysed biaryl intramolecular coupling22 of 
N-arylalkylisatins such as 7-iodo-N-(1-naphthylmethyl)isatin (33) 
and 7-iodo-N-(2-naphthylmethyl)isatin (37). The precursor 33 
was readily accessed by N-alkylation of 32, and the reactive C3 
carbonyl12, 22 was then protected as a cyclic ketal to afford 34 
(Scheme 6). 
Reaction of the isatin 34 with Pd(OAc)2 enabled an 
intramolecular biaryl coupling to take place with the possibility 
of two regioisomers being formed. The 1H NMR spectral data 
indicated the isomer produced in high yield was the 
benzopyrrolophenanthridine 35. The aromatic proton signals for 
H9' (7.56 ppm) and H10' (7.50 ppm) in 35 were observed as 
triplets which were coupled to one another.  
Under acidic conditions the ketal moiety in 35 was 
hydrolysed to yield the target 36, a new heterocyclic ring system, 
as a dark red powder (Scheme 6). The red colour of the 
compound is strong evidence that the ketal had been destroyed 
and that the C4 carbonyl, an important element in the 
chromophore of the isatin core, had been restored. Bromination 
of 36 was unsuccessful due to the poor solubility of the substrate 




Scheme 6. (a) NaH, DMF, RT, 20 min; (b) 1-(chloromethyl)naphthalene, KI, 
60 ºC, 18 h, 58% (over 2 steps); (c) (CH2OH)2, PTSA, PhMe, reflux, 48 h, 
75%; (d) Pd(OAc)2, TBAB, NaOAc, DMF, 90 ºC, 5 h, 86%; (e) 6 M 
HCl/THF (1:1), reflux, 5 h, 67%. 
 
The isomeric benzopyrrolophenanthridine dione 40 
could also be accessed by biaryl coupling using 7-iodo-N-(2-
naphthylmethyl)isatin (37) (Scheme 7). Again, the 
N-naphthylmethylisatin 37 was subjected to Dean-Stark 
conditions to protect the ketone as a cyclic ketal prior to biaryl 
coupling. As with the related compound 36, the intramolecular 
biaryl coupling of 38 could lead to two regioisomers. A pair of 
coupled doublets (H8' and H9' at 7.21 and 7.74 ppm respectively) 
and two triplet signals coupled to each other (H11' and H12' at 
7.50 and 7.56 ppm respectively) were observed in the 1H NMR 
spectrum, which is consistent with the exclusive formation of 
isomer 39 (Scheme 7). The regioselectivity of this reaction is in 
accordance with results for similar pyrrolophenanthridine 
reactions reported by Torres et al.12  
Acid-promoted cleavage of the ketal functionality in 39 
afforded, in high yield, the benzopyrrolophenanthridine 40 
(Scheme 7). The benzopyrrolophenanthridine 40 had higher 
solubility in organic solvents relative to the isomer 36 and 
consequently was readily brominated, to produce the 2-bromo 
derivative 41 (Scheme 7); no evidence for bromination of the 







Scheme 7. (a) NaH, DMF, RT, 20 min; (b) 2-(bromomethyl)naphthalene, KI, 
60 ºC, 18 h, 36% (over 2 steps); (c) (CH2OH)2, PTSA, PhMe, reflux, 64 h, 
92%; (d) Pd(OAc)2, TBAB, NaOAc, DMF, 90 ºC, 5 h, 67%; (e) 6 M 
HCl/THF (1:1), reflux, 5 h, 90%; (f) NBS, CH3CN, RT, 18 h, 39%. 
 
2.4. Biological results 
Preliminary cytotoxicity testing of the 20 tricyclic/polycyclic 
isatins was carried out on the U937 human histiocytic lymphoma 
cell line using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS assay) (Table 1). This cell line has 
been utilised previously within our research group1b-d to screen 
the in vitro cytotoxicity of isatin derivatives. 
Table 1  
Cytotoxicity of the tricyclic/polycyclic isatin derivatives against U937 cells 
after 24 h exposure. 
Compound IC50 (µM)
a  Compound IC50 (µM) 
Isatin 5651b 18 28.6 (± 2.9) 
5-Bromoisatin 64.51b 21 33.2 (± 9.5) 
2 > 577 23 77.8 (± 6.2) 
3 111 (± 53) 26 7.21 (± 0.74) 
5 278 (± 23) 27 3.01 (± 1.1) 
6 8.36 (± 3.5) 30 46.4 (± 12) 
9 106 (± 30) 31 19.7 (± 2.6) 
11 99.3 (± 3.9) 36 > 114 
12 15.3 (± 11) 40 23.4 (± 9.8) 
14 57.1 (± 14) 41 18.2 (± 4.7) 
15 59.3 (± 8.6) Vinblastine  6.881c 
17 19.3 (± 0.70)   
aIC50 values were calculated from sigmoidal dose–response curves (variable 
slope) generated using GraphPad Prism 5.00 (GraphPad Software Inc., San 
Diego, CA, USA). Values are the mean of at least two independent 
experiments performed in triplicate ± SEM. 
 
The 6,5,5-fused tricyclic isatin, pyrrolo[3,2,1-hi]indole-
1,2-dione (2) was inactive against U937 cells with an IC50 value 
of > 577 µM (beyond testing limits), while the brominated 
analogue 3 displayed an IC50 value of 111 µM, a 5-fold increase 
in cytotoxicity. However, isatin and 5-bromoisatin have IC50 
values of 565 µM and 64.5 µM respectively, against the same 
cell line,1b establishing that the tricyclic analogues 2 and 3 are 
less active than the parent isatin molecules. Conversely, the 
6,5,6-fused tricyclic isatin, pyrrolo[3,2,1-ij]quinoline-1,2-dione 
(5), displayed at least a 2-fold increase in cytotoxicity compared 
to 2 and is more active than the parent molecule, isatin. The 
brominated derivative 6 exhibited a 33-fold increase in activity 
when compared to 5. A similar pattern was observed for 
polycyclic compounds where the brominated derivatives 
displayed greater cytotoxicity (up to 2.4 times) than their parent 
molecules (i.e. 27 vs. 26; 31 vs. 30; 41 vs. 40). 
The introduction of a double bond into compounds 14 and 
15 led to an approximate 6-fold increase in cytotoxicity when 
compared to the parent molecule 5. The inclusion of a phenyl 
substituent at the C6 position in 23 resulted in decreased 
cytotoxicity compared to the parent compound 15, while a 
methyl substituent at C6 in 21 increased activity compared to 
compound 15. 
Although more than one structural change was made in 
compound 12 (IC50 15.3 µM), it is apparent that restricting 
rotation in the N-benzyl group through ring formation in this way 
had a detrimental effect on cytotoxic potency in comparison to 
N-benzyl-5,7-dibromoisatin (IC50 1.14 µM; U937).
1c Similarly, 
incorporation of a methylene group and part of the naphthyl ring 
in the ring fusion as in compound 41 (IC50 18.2 µM) resulted in a 
deterioration of activity compared to 5,7-dibromo-N-(2-
naphthylmethyl)isatin (IC50 0.74 µM; U937).
1d 
The addition of the extra ring system in 40 increased the 
cytotoxicity 2-fold compared to 30, while the introduction of an 
additional ring in derivative 36 decreased cytotoxic activity at 
least 2.5-fold compared to 30. The pyrroloacridine 26 was greater 
than 6-fold more cytotoxic than the pyrrolophenanthridine 30 and 
both acridines (26 and 27) are highly cytotoxic (IC50 < 10 µM). 
These two compounds were significantly more cytotoxic than 
any of the tricyclic derivatives shown in Table 1 with the most 
active compound (27) having an IC50 value of 3.01 µM against 
U937 cells after 24 h, which is more potent than the anti-cancer 
drug vinblastine against the same cell line (Table 1).  
3. Conclusions 
The successful synthesis of two pyrrolo[3,2,1-hi]indole-
1,2-diones, together with eleven pyrrolo[3,2,1-ij]quinoline-1,2-
diones, two pyrrolo[3,2,1-de]acridine-1,2-diones and two 
pyrrolo[3,2,1-de]phenanthridine-4,5-diones via the Stolle isatin 
synthesis or intramolecular Heck reactions is described. Three 
other benzo[j]or[l]pyrrolo[3,2,1-de]phenanthridine-4,5-diones, 
the last system being novel, were also prepared utilizing 
Pd-mediated intramolecular biaryl coupling methodology from a 
pre-formed substituted isatin. 
In vitro toxicity of the synthsised compounds against 
U937 cells was assessed and generally, the order of cytotoxicity 
for the compounds described was pyrroloacridines > 
(benzo)pyrrolophenanthridines > pyrrolo[3,2,1-ij]quinoline-1,2-
diones > pyrrolo[3,2,1-hi]indole-1,2-diones. Bromination at the 
C5 position of the isatin nucleus increased cytotoxicity relative to 
the non-brominated analogues in all cases by 2 to 33-fold, similar 
to previously reported literature.1a, b The fused acridine-isatin 
derivative 27 was identified as a new cytotoxic structural lead for 





4. Experimental section 
4.1.  General 
Isatin, 1,2,3,4-tetrahydroquinoline, phenanthridine and 
acridine were purchased from Sigma-Aldrich Chemical Co. (St. 
Louis, MO, USA). DCM refers to dichloromethane; PS refers to 
petroleum spirit (b.p. 40-60 °C). Celite (Celite 545, particle size 
0.02-0.1 mm, Merck) was used to remove metal catalysts from 
reaction mixtures. Flash column chromatography was performed 
on silica gel 60 (230-400 mesh). Melting points were obtained 
using a Reichert melting point apparatus and are uncorrected. 
Geometry optimisation (ΔHf) of tricyclic isatins was performed 
using VAMP at semi-empirical level (AM1) on Materials Studio 
4.4 (Accelrys Inc., San Diego, CA, USA). Nuclear magnetic 
resonance (NMR) spectra were acquired on a Varian Unity 
300 MHz spectrometer or Varian Inova 500 spectrometer. The 
symbol † denotes coincident peaks. Low resolution electron 
ionisation mass spectra (LREI-MS) were obtained using a 
Shimadzu QP5050 spectrometer; high resolution electron 
ionisation mass spectra (HREI-MS) were obtained using a 
Fisons/VG Autospec spectrometer; high resolution electrospray 
ionisation spectra (HRESI-MS) were obtained using a Waters 
Q-TOF Ultima spectrometer.  
4.2 Synthesis 
4.2.1 4,5-Dihydropyrrolo[3,2,1-hi]indole-1,2-dione (2)  
 
The compound was prepared according to the method of 
Norman et al.15 to yield 2  as a red powder (845 mg, 15%), m.p. 
195-197 °C (lit.15 203-207 ºC). 1H NMR (DMSO-d6, 500 MHz): 
δ 3.38 (t, J = 7.5 Hz, 2H), 4.09 (t, J = 7.5 Hz, 2H), 6.98 (t, 
J = 7.5 Hz, 1H), 7.26 (d, J = 7.0 Hz, 1H), 7.48 (d, J = 7.0 Hz, 1H). 
The 1H NMR spectral data coincided with those reported in the 
literature.15 LREI-MS: m/z (%): 173 (22) [M+], 145 (100) [M-CO], 
117 (63). 
 
4.2.2 7-Bromo-4,5-dihydropyrrolo[3,2,1-hi]indole-1,2-dione (3) 
 
According to the method of Vine et al.,1b the cyclised 
isatin 2 (100 mg, 577 µmol) was dissolved in 95% EtOH (4 mL) 
and heated to 75 ºC. Br2 (276 mg, 88.7 µL, 1.73 mmol) was added 
drop wise while the solution was still hot. The reaction mixture 
was then cooled on ice, filtered and concentrated. The resulting 
solid was purified by flash chromatography (100% DCM) to yield 
3 as dark red crystals (47.8 mg, 33%), m.p. 162-164 °C. 1H NMR 
(DMSO-d6, 500 MHz): δ 3.38 (t, J = 7.5 Hz, 2H), 4.07 (t, 
J = 7.5 Hz, 2H), 7.49 (s, 1H), 7.66 (s, 1H). 13C NMR (DMSO-d6, 
126 MHz):  30.7, 46.7, 113.7, 115.3, 124.7, 128.3, 136.1, 155.9, 
159.3, 183.1. LREI-MS: m/z (%): 251/253 (13) [M+]79Br/81Br, 
223/225 (55) [M-CO], 195/197 (32) [M-CO], 168 (61), 116 (66), 
100 (100). HRESI-MS: m/z calcd for C10H7
79BrNO2 [M+H]
+: 
251.9660; found 251.9655. 
 
4.2.3 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (5)  
 
The compound was prepared according to the method of 
Kojima et al.23 using DCM instead of CS2 as the solvent, to yield 5  
as red crystals (437 mg, 31%), m.p. 195-197 °C (lit.23 
198-200 °C). 1H NMR (CDCl3, 500 MHz): δ 2.02-2.06 (m, 2H), 
2.77 (t, J = 6.0 Hz, 2H), 3.75 (t, J = 6.0 Hz, 2H), 6.99 (t, 
J = 7.5 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H). 
13C NMR (CDCl3, 126 MHz):  20.2, 23.9, 38.4, 115.7, 121.9, 
123.0, 123.2, 137.1, 147.6, 156.9, 183.9. LREI-MS: m/z (%): 187 
(70) [M+], 159 (60) [M-CO], 130 (100). HREI-MS: m/z calcd for 
C11H9NO2 [M





The compound was prepared according to the method for 
3 using the isatin 5 (150 mg, 801 mol) and Br2 (384 mg, 123 L, 
2.40 mmol) as starting materials. The resulting solid was purified 
by flash chromatography (100% DCM) to yield 6 as dark red 
crystals (166 mg, 78%), m.p. 201-203 °C (lit.24 185-187 °C). 
1H NMR (CDCl3, 500 MHz): δ 2.02-2.07 (m, 2H), 2.77 (t, 
J = 6.0 Hz, 2H), 3.75 (t, J = 5.5 Hz, 2H), 7.47 (s, 1H), 7.49 (s, 1H). 
13C NMR (CDCl3, 126 MHz):  20.3, 23.9, 38.7, 116.3, 117.1, 
124.3, 125.9, 139.5, 146.7, 156.4, 182.8. LREI-MS: m/z (%): 
265/267 (60) [M+]79Br/81Br, 237/239 (100) [M-CO], 209 (45), 130 





4.2.5 2-Phenyl-1,2-dihydroquinoline (8) 
 
The compound was prepared by reduction of 7 according 
to the method of Goldstein and Dambek25 to yield 8 as an 
orange/brown oil (8.67 g, 90%), b.p. ca 760 mm 155 °C.  
 
4.2.6 4-Phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (9) 
 
Dihydroquinoline 8 (1.04 g, 5.02 mmol) in anhydrous 
THF (6 mL) was added portion wise over 30 min to a refluxing 
solution of oxalyl chloride (1.27 g, 873 L, 10.0 mmol) in 
anhydrous THF (4 mL). The reaction mixture was heated at reflux 
for 3.5 h before the solvent was removed by rotary evaporation. 
The dark residue was dissolved in anhydrous CHCl3 (30 mL) and 
heated at reflux. AlCl3 (2.01 g, 15.1 mmol) was added portion 
wise over 5 h and the solution was heated at reflux for a further 
18 h. The solvent was once again removed by rotary evaporation, 
the residue was cooled on ice, concentrated HCl (10 mL) was 
added, followed by H2O (10 mL) and CHCl3 (50 mL). The phases 
were separated and the organic layer was washed with H2O 
(2 × 50 mL), dried over MgSO4, filtered and the solvent removed 
by rotary evaporation. The resulting solid was purified by flash 
chromatography (100% DCM) to yield 9 as dark red crystals 
(15.7 mg, 1%), m.p. 74-76 °C. 1H NMR (CDCl3, 500 MHz): δ 
5.83 (dd, J = 3.2 Hz, 10.0 Hz, 1H), 5.88 (d, J = 3.2 Hz, 1H), 6.52 
(d, J = 10.0 Hz, 1H), 6.99 (t, J = 8.0 Hz, 1H), 7.29 (d, J = 7.5 Hz, 
1H), 7.33 (d, J = 6.5 Hz, 1H), 7.35-7.38 (m, 3H), 7.44 (d, 
J = 7.5 Hz, 2H). 13C NMR (CDCl3, 126 MHz): δ 56.0, 114.8, 
118.0, 120.1, 123.6, 124.1, 127.3,† 127.4, 128.7, 129.0,† 133.7, 
139.2, 147.3, 157.4, 182.4. LREI-MS: m/z (%): 261(32) [M+], 232 
(43), 204 (100), 156 (59). HRESI-MS: m/z calcd for C17H12NO2 
[M+H]+: 262.0868; found 262.0858. 
 
4.2.7 2-Phenyl-1,2,3,4-tetrahydroquinoline (10) 
 
The compound was prepared by reduction of  8 
according to the method of Goldstein and Dambek25  to yield 10 as 
a yellow/orange oil (3.18 g, 70%), b.p. ca 760 mm 192 °C  (lit.
25 b.p. 
2 mm 176 °C). 
1H NMR (CDCl3, 500 MHz): δ 1.93-2.02 (m, 2H), 
2.73-2.78 (m, 2H), 3.97 (bs, 1H), 4.44 (dd, J = 2.5 Hz, 9.0 Hz, 
1H), 6.46-6.67 (m, 2H), 6.94-7.03 (m, 2H), 7.22-7.41 (m, 5H). The 
1H NMR spectral data coincided with those reported in the 





The compound was prepared according to the method for 




1.66 mL, 19.1 mmol) as starting materials. The resulting solid was 
purified by flash chromatography (100% DCM) to yield 11  as 
dark red crystals (120 mg, 5%), m.p. 139-140 °C (lit.23 
129-130 °C). 1H NMR (CDCl3, 500 MHz): δ 2.16-2.22 (m, 1H), 
2.26-2.29 (m, 1H), 2.47-2.53 (m, 1H), 2.63-2.66 (m, 1H), 5.47 
(app. bs, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 7.5 Hz, 2H), 
7.27 (t, J = 7.0 Hz, 1H), 7.32 (t, J = 7.0 Hz, 2H), 7.35 (d, 
J = 7.5 Hz, 1H), 7.47 (d, J = 7.5 Hz, 1H). 13C NMR (CDCl3, 
126 MHz):  19.8, 27.7, 51.6, 115.6, 122.0, 123.2, 123.2, 125.4,† 
127.8, 128.9,† 137.2, 139.1, 147.8, 156.8, 183.6. LREI-MS: m/z 
(%): 263 (79) [M+], 206 (100). HREI-MS: m/z calcd for 
C17H13NO2 [M





The compound was prepared according to the method for 
6 using the isatin 11 (65.2 mg, 248 mol) and Br2 (119 mg, 
38.3 L, 7.44 mol) as starting materials. The resulting solid was 
purified by flash chromatography (100% DCM) to yield 12 as red 
crystals (42.3 mg, 50%), m.p. 60-62 °C. 1H NMR (CDCl3, 
500 MHz): δ 2.15-2.19 (m, 1H), 2.26-2.29 (m, 1H), 2.50-2.53 (m, 
1H), 2.62-2.66 (m, 1H), 5.46 (s, 1H), 7.14 (d, J = 7.5 Hz, 2H), 
7.27-7.29 (m, 1H), 7.32 (d, J = 7.5 Hz, 2H), 7.50 (s, 1H), 7.59 (s, 
1H). 13C NMR (CDCl3, 126 MHz):  19.7, 27.6, 38.7, 116.2, 
116.7, 124.2, 125.3,† 125.9, 128.0, 129.0,† 132.3, 139.4, 146.7, 
156.0, 182.3. LREI-MS: m/z (%): 341/343 (42) [M+]79Br/81Br, 
313/315 (30) [M-CO], 284/286 (72), 204 (43), 102 (100). 





4.2.10 1-Allyl-7-bromo-1H-indole-2,3-dione (13) 
 
  A mixture of 7-bromoisatin (19) (250 mg, 1.11 mmol) 
and NaH (62.3 mg, 1.55 mmol) was dissolved in anhydrous DMF 
(6 mL) and stirred at RT for 20 min before the addition of KI 
(37.2 mg, 222 mol) and allyl bromide (295 mg, 211 L, 
2.44 mmol). The reaction mixture was heated at 60 °C and stirred 
at this temperature for 18 h. After cooling, EtOAc (25 mL) was 
added and the resulting solution was extracted with 0.5 M HCl 
(25 mL), followed by brine (25 mL). The orange organic layer was 
dried over MgSO4 and the solvent was removed by rotary 
evaporation to yield a sticky red residue. The resulting solid was 
purified by flash chromatography (100% DCM) to yield 13 as 
orange crystals (236 mg, 81%), m.p. 112-114 °C. 1H NMR 
(CDCl3, 500 MHz): δ 4.80-4.81 (m, 2H), 5.245 (d, J = 11.5 Hz, 
1H), 5.246 (d, J = 16.0 Hz, 1H), 5.95-6.02 (m, 1H), 7.00 (t, 
J = 7.5 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.5 Hz, 1H). 
13C NMR (CDCl3, 126 MHz): δ 43.4, 104.5, 117.7, 120.9, 124.9, 
125.3, 132.0, 144.2, 148.0, 158.7, 182.6. LREI-MS: m/z (%): 
265/267 (66) [M+]79Br/81Br, 224/226 (100) [M-CH2CHCH2], 
168/170 (50) (M-CH2CHCH2-(CO)2). HREI-MS: m/z calcd for 
C11H8
79BrNO2
 [M+]: 264.9738; found 264.9736. 
 
4.2.11 4H-Pyrrolo[3,2,1-ij]quinoline-1,2-dione (14) and 
6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (15) 
 
The isatin 13 (150 mg, 564 mol), TBACl (157 mg, 
564 mol), K2CO3 (234 mg, 1.69 mmol) and Pd(OAc)2 (12.7 mg, 
56.4 mol) were dissolved in anhydrous DMF (7 mL) and heated 
at 85 °C for 2 h. Upon cooling, DCM (50 mL) was added and the 
solution was extracted with H2O (3 × 15 mL) and brine 
(1 × 15 mL). The organic layer was dried over MgSO4, the 
suspension filtered and the solvent removed by rotary evaporation. 
The resulting solid was purified by flash chromatography and 
preparative TLC (100% DCM) to yield 14 (41.1 mg, 39%) and 15 
(13.6 mg, 13%) as dark red crystals, m.p. 194-196 °C. 1H NMR 
(CDCl3, 500 MHz): 14: δ 4.62 (t, J = 3.0 Hz, 2H), 5.84 (dt, 
J = 10.5 Hz, 3.5 Hz, 1H), 6.40 (dt, J = 10.5 Hz, 2.5 Hz, 1H), 6.93 
(t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 7.5 Hz, 
1H); 15: δ 3.60 (d, J = 2.5 Hz, 2H), 5.29-5.32 (m, 1H), 6.94-6.95 
(m, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.47 (d, 
J = 7.5 Hz, 1H). 13C NMR (CDCl3, 126 MHz): 14:  41.2, 114.7, 
118.3, 121.7, 123.2, 123.8, 124.1, 133.7, 148.5, 157.6, 182.6.  15: 
 24.8, 108.5, 116.2, 118.0, 119.1, 123.6, 125.9, 136.7, 144.6, 
153.2, 182.8. LREI-MS: m/z (%): 14: 185 (20) [M+], 156 (48), 85 
(36), 71 (36), 71 (64), 57 (100), 43 (80). 15: 185 (31) [M+], 156 
(100), 128 (38). HREI-MS: m/z calcd for C11H7NO2 [M
+]: 
185.0477; found 185.0471 (4H isomer, 14), 185.0474 (6H isomer, 
15). 
 
4.2.12 1-Allyl-5,7-dibromo-1H-indole-2,3-dione (16) 
 
The compound was prepared according to the method for 
13 using 5,7-dibromoisatin (1.50 g, 4.92 mmol), NaH (165 mg, 
6.89 mmol), KI (163 mg, 984 mol) and allyl bromide (1.31 g, 
937 L, 10.8 mmol) as starting materials. The resulting solid was 
purified by flash chromatography (100% DCM) to yield 16  as red 
crystals (1.48 g, 87%), m.p. 98-100 °C, (lit.1c 103-105 °C). 
1H NMR (CDCl3, 300 MHz): δ 4.78 (d, J = 4.8 Hz, 2H), 5.23 (d, 
J = 17.1 Hz, 1H), 5.25 (d, J = 9.9 Hz, 1H), 5.90-6.03 (m, 1H), 7.69 
(br s, 1H), 7.85 (br s, 1H). The 1H NMR spectral data were close 
to those reported in the literature.1c LREI-MS: m/z 343/345/347 
[M+]79Br79Br/79Br 81Br;/81Br 81Br. 
 
4.2.13 8-Bromo-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione  (17) and 
8-bromo-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (18) 
 
These compounds were prepared according to the 
method for 14 and 15 using the isatin 16 (150 mg, 435 mol), 
TBACl (121 mg, 435 mol), K2CO3 (181 mg, 1.31 mmol) and 
Pd(OAc)2 (9.80 mg, 43.5 mol) as starting materials. The resulting 
solid was purified by flash chromatography (CHCl3/PS, 2:1) and 
preparative TLC (100% DCM) to yield 17 (33.4 mg, 29%) and 18 
(22.4 mg, 20%) as dark red crystals, m.p. 215-217 °C. 1H NMR 
(CDCl3, 500 MHz): 17: δ 4.63 (brd, J = 2.5 Hz, 2H), 5.89 (dt, 
J = 11 Hz, 2.5 Hz, 1H), 6.35 (brd, J = 11 Hz, 1H), 7.29 (s, 1H), 
7.42 (s, 1H); 18: δ 3.59 (app. bs, 2H), 5.29-5.32 (m, 1H), 6.93 (d, 
J = 8.5 Hz, 1H), 7.50 (s, 1H), 7.59 (s, 1H). 13C NMR (CDCl3, 
126 MHz): 17:  41.2, 115.8, 116.6, 120.2, 120.8, 124.7, 126.5, 
135.8, 146.4, 156.8, 181.3. 18:  24.8, 108.5, 118.2, 119.2, 121.4, 
122.8, 126.6, 139.3, 148.5, 158.4, 182.0. LREI-MS: m/z (%): 17: 
263/265 (38) [M+] 79Br/81Br, 234/236 (100). 18: 263/265 (27) 
[M+] 79Br/81Br, 234/236 (100), 180 (91). HRESI-MS: m/z calcd for 
C11H7
79BrNO2 [M+H]
+: 263.9660; found 263.9659 (4H isomer, 
17), m/z calcd for C11H7
81BrNO2 [M+H]
+: 265.9640; found 
265.9804 (6H isomer, 18). 
 
4.2.14 7-Bromo-1H-indole-2,3-dione (19) 
Chloral hydrate (5.01 g, 30.2 mmol) and Na2SO4 (35.0 g, 
246 mmol) were dissolved in H2O (70 mL) in a 300 mL beaker 
and heated to 35 °C. 2-Bromoaniline (4.75 g, 3.12 mL, 27.6 mmol) 
in H2O (20 mL) and concentrated HCl (3 mL) were warmed and 
added to the reaction mixture. Hydroxylamine HCl (6.10 g, 
87.8 mmol) in H2O (27.5 mL) was warmed and added before the 
mixture was heated at 85 °C for 3 h. The mixture was cooled, 
filtered and washed with H2O (100 mL) to yield the intermediate 
(5.75 g, 86%) as a fluffy light brown powder. Concentrated H2SO4 
(100 mL) was heated in a 1 L beaker to 60 °C. The intermediate 
was added in portions over 15 min so the temperature did not 




15 min before being poured into ice (500 mL). The precipitate 
was washed with H2O (100 mL) to yield 19 as a fine dark red 
powder (2.94 g, 47%), m.p. 192-194 °C (lit.26 195-200 °C). 1H 
NMR (DMSO-d6, 500 MHz): δ 7.02 (t, J = 7.5 Hz, 1H), 7.51 (d, 
J = 7.5 Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H), 11.31 (bs, 1H). The 1H 
NMR spectral data coincided with those reported in the 
literature.27  LREI-MS: m/z 225/227 [M+]79Br/81Br. 
 
4.2.15 (E)-7-Bromo-1-(but-2-enyl)-1H-indole-2,3-dione (20) 
 
  The compound was prepared according to the method for 
13 using 7-bromoisatin (19) (500 mg, 2.21 mmol), NaH (74.2 mg, 
3.09 mmol), KI (73.4 mg, 442 mol) and crotyl bromide (656 mg, 
500 L, 4.86 mmol) as starting materials. The resulting solid was 
purified by flash chromatography (100% DCM) to yield 20 as 
orange crystals (363 mg, 59%), m.p. 71-73 °C. 1H NMR (CDCl3, 
500 MHz): δ 1.69 (d, J = 6.0 Hz, 3H), 4.73 (d, J = 4.5 Hz, 2H), 
5.61-5.64 (m, 1H), 5.74-5.80 (m, 1H), 6.99 (t, J = 7.5 Hz, 1H), 
7.58 (d, J = 7.5 Hz, 1H), 7.69 (d, J = 7.5 Hz, 1H). 13C NMR 
(CDCl3, 126 MHz):  17.8, 42.6, 104.2, 120.7, 124.6, 124.7, 
124.9, 129.9, 143.9, 147.9, 158.5, 182.7. LREI-MS: m/z (%): 
279/281 (42) [M+]79Br/81Br, 224/226 (100), 168/170 (24), 75 (39). 





4.2.16 6-Methyl-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (21) 
 
The compound was prepared according to the method for 
14 and 15 using the isatin 20 (161 mg, 575 mol), K2CO3 
(239 mg, 1.73 mmol), TBACl (160 mg, 575 mol) and Pd(OAc)2 
(12.9 mg, 57.5 mol) as starting materials. The resulting solid was 
purified by flash chromatography and preparative TLC (100% 
DCM) to yield 21 as a dark red powder (9.30 mg, 8%), m.p. 
96-97 °C. 1H NMR (CDCl3, 500 MHz): δ 1.43 (d, J = 7.5 Hz, 3H), 
3.73-3.75 (m, 1H), 5.21 (dd, J = 2.5 Hz, 8.5 Hz, 1H), 6.90 (dd, 
J = 2.5 Hz, 8.5 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.43 (d, 
J = 7.5 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H). 13C NMR (CDCl3, 
126 MHz):  23.6, 29.8, 114.7, 116.0, 116.3, 123.4, 124.6, 126.0, 
136.1, 143.8, 153.2, 182.8. LREI-MS: m/z (%): 199 (16) [M+], 184 
(16) [M-CH3], 156 (60) [M-CH3-CO], 85 (60), 71 (100), 69 (86). 
HRESI-MS: m/z calcd for C12H10NO2 [M+H]
+: 200.0712; found 
200.0659. 
 
4.2.17 (E)-7-Bromo-1-(3-phenyl-allyl)-1H-indole-2,3-dione (22) 
 
The compound was prepared according to the method for 
13 using 7-bromoisatin (19) (751 mg, 3.33 mmol), NaH (186 mg, 
4.66 mmol), KI (111 mg, 670 mol) and cinnamyl bromide 
(1.45 g, 1.09 mL, 7.33 mmol) as starting materials. The resulting 
solid was purified by flash chromatography (100% DCM) to yield 
22 as an orange powder (551 mg, 48%), m.p. 149-151 °C. 
1H NMR (CDCl3, 500 MHz): δ 4.96 (d, J = 6.0 Hz, 2H), 6.30-6.36 
(m, 1H), 6.66 (d, J = 16 Hz, 1H), 7.01 (t, J = 7.0 Hz, 1H), 7.24 (t, 
J = 7.5 Hz, 1H) 7.30 (t, J = 7.5 Hz, 2H), 7.35 (d, J = 7.5 Hz, 2H), 
7.60 (d, J = 7.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H). 13C NMR 
(CDCl3, 126 MHz):  47.8, 104.2, 120.8, 123.0, 124.7, 125.1, 
126.5,† 128.0, 128.6,† 133.5, 136.2, 144.0, 147.7, 158.6, 182.5. 
LREI-MS: m/z (%): 341/343 (16) [M+]79Br/81Br, 224/226 (56) 
[M-CH2CHCHC6H5], 117 (100). HREI-MS: m/z calcd for 
C17H12
79BrNO2 [M
+]: 341.0051; found 341.0055. 
 
4.2.18 6-Phenyl-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (23) 
 
The compound was prepared according to the method for 
14 and 15 using the isatin 22 (130 mg, 380 mol), K2CO3 
(158 mg, 1.14 mmol), TBACl (106 mg, 380 mol) and Pd(OAc)2 
(8.50 mg, 38.0 mol) as starting materials. The resulting solid was 
purified by flash chromatography (CHCl3/PS, 3:2) and preparative 
TLC (100% DCM) to yield 23 as orange/red crystals (17.2 mg, 
17%), m.p. 130-132 °C. 1H NMR (CDCl3, 500 MHz): δ 4.88 (bs, 
1H), 5.33 (dd, J = 4.0 Hz, 8.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 
7.12 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.25 (d, 
J = 7.5 Hz, 2 H), 7.29 (d, J = 7.0 Hz, 1H), 7.36 (t, J = 7.5 Hz, 2H), 
7.48 (d, J = 7.0 Hz, 1H). 13C NMR (CDCl3, 126 MHz):  41.7, 
112.8, 116.2, 116.5, 123.7, 126.1, 127.5, 128.3,† 128.9, 129.0,† 
137.5, 143.4, 147.6, 153.4, 182.5. LREI-MS: m/z (%): 261 (16) 
[M+], 233 (33) [M-CO], 168 (50), 156 (50), 100 (100). 
HRESI-MS: m/z calcd for C17H12NO2 [M+H]
+: 262.0868; found 
262.0855. 
 
4.2.19 9,10-Dihydroacridine (25) 
 
A mixture of acridine (24) (10.0 g, 55.8 mmol) and 
AcOH (6.01 g, 5.73 mL, 100 mmol) were added to absolute EtOH 
(100 mL) and heated at reflux for 30 min before the addition of 
NaCNBH3 (6.66 g, 106 mmol). The solution was heated at reflux 
for a further 1.5 h, cooled and the solvent removed by rotary 
evaporation. The white residue was basified with aqueous NH3 
(200 mL) and extracted with Et2O (3 × 100 mL). The organic 
extract was evaporated and the white precipitate was recrystallised 
from 95% EtOH to yield 25 as cream coloured needles (4.76 g, 
47%), m.p. 171-172 °C (lit.28 166-169 °C). 1H NMR (CDCl3, 
500 MHz): δ 4.06 (s, 2H), 5.95 (bs, 1H), 6.67 (d, J = 8.0 Hz, 2H), 
6.86 (t, J = 7.5 Hz, 2H), 7.06-7.11 (m, 4H). The 1H NMR spectral 
data coincided with those reported in the literature.29 LREI-MS: 
m/z (%): 180 (100) [M-H]+. 
 
4.2.20 6H-Pyrrolo[3,2,1-de]acridine-1,2-dione (26) 
 
The compound was prepared according to the method for 
9 using 9,10-dihydroacridine (25) (4.50 g, 24.8 mmol) and oxalyl 
chloride (6.30 g, 4.33 mL, 49.6 mmol) as starting materials. The 
resulting solid was purified by flash chromatography (100% 
CHCl3) to yield 26 as dark red crystals (857 mg, 15%), m.p. 
204-206 °C, (lit.10b 208-210 °C). The 1H NMR spectral data 
coincided with those reported in the literature.10b 1H NMR (CDCl3, 
500 MHz): δ 4.21 (s, 2H), 7.14-7.33 (m, 4H), 7.45 (d, J = 7.5 Hz, 
1H), 7.52 (d, J = 7.5 Hz, 1H), 8.68 (d, J = 8.0 Hz, 1H). LREI-MS: 
m/z (%): 235 (29) [M+], 207 (100) [M-CO].  
 
4.2.21 4-Bromo-6H-pyrrolo[3,2,1-de]acridine-1,2-dione (27) 
 
The compound was prepared according to the method for 
6 using 26 (100 mg, 425 mol), glacial AcOH (5 mL) and Br2 
(205 mg, 65.9 L, 1.28 mmol) as starting materials. The resulting 
solid was purified by flash chromatography (100% CHCl3) to yield 
27 as a dark red powder (54.6 mg, 41%), m.p. 190-192 °C. 
1H NMR (CDCl3, 500 MHz): δ 4.20 (s, 2H), 7.22 (t, J = 7.5 Hz, 
1H), 7.41-7.47 (m, 3H), 7.55 (t, J = 7.0 Hz, 1H), 8.57 (d, 
J = 8.5 Hz, 1H). 13C NMR (CDCl3, 126 MHz): δ 28.1, 116.1, 
118.9,† 119.1, 123.4, 123.9, 125.7, 131.1, 131.3,  132.5, 136.8, 
145.1, 155.4, 181.8. LREI-MS: m/z (%): 313/315 (25) 
[M+]79Br/81Br, 285/287 (100) [M-CO], 206 (55) [M-CO-Br], 177 
(55), 151 (43), 103 (48), 89 (85), 75 (80). HRESI-MS: m/z calcd 
for C15H9
79BrNO2 [M+H]
+: 313.9817; found 313.9807. 
 
4.2.22 5,6-Dihydrophenanthridine (29) 
 
The compound was prepared according to the method for 
25 using phenanthridine (28) (5.00 g, 27.9 mmol), AcOH (1.68 g, 
1.60 mL, 27.9 mmol) and NaCNBH3 (3.33 g, 53.1 mmol) as the 




from 95% EtOH to yield 29 as yellow crystals (3.89 g, 77%), m.p. 
64-66 °C (lit.30 89-90 °C). 1H NMR (CDCl3, 500 MHz): δ 3.72 (s, 
1H), 4.39 (s, 2H), 6.66-6.68 (m, 1H), 6.82-6.86 (m, 1H), 7.09-7.12 
(m, 2H), 7.20-7.23 (m, 1H), 7.30-7.33 (m, 1H), 7.68-7.70 (m, 2H). 
The 1H NMR spectral data coincided with those reported in the 
literature.31 LREI-MS: m/z (%): 181 (65) [M+], 180 (100) [M-H], 
152 (33) [M-H-CO]. 
 
4.2.23 7H-Pyrrolo[3,2,1-de]phenanthridine-4,5-dione (30) 
 
A mixture of 5,6-dihydrophenanthridine (29) (500 mg, 
2.76 mmol), oxalyl chloride (701 mg, 482 L, 5.52 mmol), DMAP 
(33.7 mg, 276 mol) and DIPEA (357 mg, 480 L, 2.76 mmol) 
was dissolved in anhydrous THF (10 mL) and heated at reflux for 
3.5 h. The solution was evaporated and the residue was dissolved 
in anhydrous CHCl3 (40 mL) and heated at reflux. AlCl3 (1.10 g, 
8.28 mmol) was added portion wise over 30 min and the solution 
was heated at reflux for a further 1.5 h. Upon cooling, the solution 
was extracted with H2O (2 × 25 mL) and brine (1 × 25 mL). The 
organic extract was dried over MgSO4, filtered and evaporated. 
The resulting solid was purified using flash chromatography 
(100% DCM) to yield 30 as dark red crystals (100 mg, 15%), m.p. 
212-214 °C. 1H NMR (CDCl3, 500 MHz): δ 5.06 (s, 2H), 7.09 (t, 
J = 7.5 Hz, 1H), 7.19 (d, J = 7.5 Hz, 1H), 7.33 (t, J = 7.0 Hz, 1H), 
7.37 (t, J = 7.5 Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 7.76 (d, 
J = 8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H). 13C NMR (CDCl3, 
126 MHz):  42.6, 116.5, 118.9, 122.8, 124.3, 124.7, 126.9, 128.1, 
128.4, 128.7, 129.6, 130.7, 146.6, 157.9, 183.2. LREI-MS: 
m/z (%): 235 (50) [M+], 206 (100), 179 (33). HREI-MS: m/z calcd 
for C15H9NO2





The compound was prepared according to the method for 
6 using 30 (84.0 mg, 357 mol), glacial AcOH (5 mL) and Br2 
(171 mg, 55.0 L, 1.07 mmol) as starting materials. The resulting 
solid was purified by flash chromatography (100% CHCl3) to yield 
31 as dark red powder (77.1 mg, 69%), m.p. 239-241 °C. 1H NMR 
(CDCl3, 300 MHz): δ 5.08 (s, 2H), 7.19-7.22 (m, 1H), 7.37-7.39 
(m, 2H), 7.53 (s, 1H), 7.70-7.73 (m, 1H), 7.98 (s, 1H). 13C NMR 
(CDCl3, 75 MHz): δ 42.4, 117.1, 117.3, 120.7, 122.8, 125.6, 126.9, 
128.0, 128.5, 128.7, 130.1, 132.8, 145.2, 156.8, 181.7. LREI-MS: 
m/z (%): 313/315 (52) [M+]79Br/81Br, 284/286 (100), 257 (37), 177 
(48), 150 (44). HREI-MS: m/z calcd for C15H8
81BrNO2 [M
+]: 
314.9718; found 314.9731. 
 
4.2.25 7-Iodo-1H-indole-2,3-dione (32)  
 
The compound was prepared according to the method for 
19 using chloral hydrate (6.67 g, 40.3 mmol), Na2SO4 (46.2 g, 
325 mmol), 2-iodoaniline (8.00 g, 36.5 mmol) and hydroxylamine 
HCl (8.13 g, 117 mmol) as starting materials, to yield 32 as a dark 
red/brown powder (5.77 g, 58%), m.p. 205-206 °C (lit.32 208 °C). 
1H NMR (DMSO-d6, 500 MHz): δ 6.89 (t, J = 7.5 Hz, 1H), 7.49 
(d, J = 7.5 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 11.00 (bs, 1H). The 
1H NMR spectral data coincided with those reported in the 
literature.33 LREI-MS: m/z 273 [M+]. 
 
4.2.26 7-Iodo-1-(naphthalen-1-ylmethyl)-1H-indole-2,3-dione (33) 
 
This compound was prepared according to the method 
for 13 using 32 (6.00 g, 22.0 mmol), NaH (739 mg, 30.8 mmol), 
KI (730 mg, 4.40 mmol) and 1-(chloromethyl)naphthalene (8.11 g, 
6.87 mL, 48.4 mmol) as starting materials. The resulting solid was 
purified by flash chromatography (100% CHCl3) to yield 33 as a 
red powder (5.29 g, 58%), m.p. 177-178 °C, Rf 0.21. 
1H NMR 
(CDCl3, 500 MHz): δ 5.89 (s, 2H), 6.90 (t, J = 8.0 Hz, 1H), 7.10 
(d, J = 7.0 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.56 (t, J = 7.5 Hz, 
1H), 7.62 (t, J = 7.5 Hz, 1H), 7.72 (d, J = 7.0 Hz, 1H), 7.81 (d, 
J = 8.5 Hz, 1H), 7.92 (dd, J = 3.5 Hz, 8.5 Hz, 2H), 7.99 (d, 
J = 8.0 Hz, 1H). 13C NMR (CDCl3, 126 MHz):  42.1, 74.1, 120.6, 
121.9, 122.3, 125.4, 125.5, 125.6, 126.1, 126.6, 128.1, 129.0, 
130.0, 131.0, 133.9, 151.0, 151.1, 158.9, 182.4.  LREI-MS: m/z 
(%): 413 (58) [M+], 272 (87) [M-CH2C10H7], 141 (100). 
HRESI-MS: m/z calcd for C19H12INO2 [M]






According to the method of Ribeiro et al.,34 the isatin 33 
(4.96 g, 12.0 mmol), ethylene glycol (14.9 g, 13.4 mL, 240 mmol) 
and PTSA (496 mg, 10% of starting material weight) were 
dissolved in PhMe (40 mL) and heated at reflux under Dean-Stark 
conditions for 24 h. No evidence of product had formed so more 
ethylene glycol was added (7.45 g, 6.70 mL, 120 mmol) and the 
solution was heated at reflux for a further 24 h before the solvent 
was removed by rotary evaporation. The resulting solid was 
purified by flash chromatography (100% DCM) to yield 34 as a 
beige powder (4.14 g, 75%), m.p. 236-238 °C. 1H NMR (CDCl3, 
500 MHz): δ 4.38 (t, J = 7.0 Hz, 2H), 4.63 (t, J = 6.5 Hz, 2H), 5.77 
(s, 2H), 6.83 (d, J = 7.5 Hz, 1H), 7.05 (d, J = 7.5 Hz, 1H), 7.37 (t, 
J = 7.5 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.53 (t, J = 7.0 Hz, 1H), 
7.60 (t, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.77 (d, 
J = 8.0 Hz, 1H), 7.90 (d, J = 7.5 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H). 
13C NMR (CDCl3, 126 MHz):  41.9, 66.3,
† 72.8, 101.2, 122.3, 
122.7, 125.2, 125.4, 125.9, 126.0, 126.5, 127.5, 127.8, 129.1, 
130.4, 131.9, 134.0, 144.7,† 174.5. LREI-MS: m/z (%): 457 (21) 
[M+], 316 (100) [M-CH2C10H7], 272 (37) [M-CH2C10H7-(CH2)2O], 
141(34). HRESI-MS: m/z calcd for C21H17INO3 [M+H]
+: 





The ketal 34 (2.00 g, 4.37 mmol), Pd(OAc)2 (98.0 mg, 
437 µmol), TBAB (1.55 g, 4.81 mmol) and NaOAc (1.79 g, 
21.9 mmol) were dissolved in anhydrous DMF (44 mL) and heated 
at 90 ºC for 5 h. Upon cooling, H2O (200 mL) was added and the 
solution was extracted with EtOAc (3 × 100 mL). The organic 
extract was dried over MgSO4, filtered and evaporated. The 
resulting solid was purified using flash chromatography (100% 
CHCl3) to yield 35 as a light brown powder (1.24 g, 86%), 
m.p. 222-224 °C. 1H NMR (CDCl3, 500 MHz): δ 4.36 (t, 
J = 6.5 Hz, 2H), 4.63 (t, J = 6.5 Hz, 2H), 5.27 (s, 2H), 7.08 (t, 
J = 7.0 Hz, 1H), 7.25 (d, J = 7.5 H, 1H), 7.50 (t, J = 8.0 Hz, 1H), 
7.56 (t, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.79-7.84 (m, 
3H). 13C NMR (CDCl3, 126 MHz):  40.7, 65.9,
† 103.2, 117.4, 
120.0, 122.3, 122.4, 123.4, 123.5, 124.3, 124.5, 125.2, 126.4, 
127.3, 128.7, 128.8, 130.3, 133.0, 139.3, 183.2. LREI-MS: m/z 
(%): 329 (33) [M+], 300 (100), 256 (33), 229 (30), 201 (57), 128 
(30), 114 (33). HRESI-MS: m/z calcd for C21H16NO3
 [M+]: 





The cyclised ketal 35 (1.10 g, 3.34 mmol) was dissolved 
in 6 M HCl/THF (1:1, 35 mL) and heated at reflux for 5 h. Upon 
cooling, H2O (200 mL) was added, the solution filtered and 




(641 mg, 67%), m.p. 251-253 °C. 1H NMR (CDCl3, 500 MHz): 
δ 5.44 (s, 2H), 7.14 (t, J = 7.5 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 
7.62 (t, J = 7.0 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.95 (d, 
J = 8.5 Hz, 1H), 8.01 (t, J = 7.5 Hz, 2H), 8.16 (d, J = 9.0 Hz, 1H), 
8.25 (d, J = 8.0 Hz, 1H). 13C NMR (CDCl3, 126 MHz):  40.8, 
115.7, 118.7, 119.6, 122.4, 123.4, 124.4, 124.7, 127.0, 127.8, 
129.2, 129.9, 130.2, 130.8, 133.3, 134.2, 146.5, 157.8, 182.9. 
LREI-MS: m/z (%): 285 (55) [M+], 256 (100), 229 (38), 201 (32), 
128 (23), 114 (40), 100 (43). HRESI-MS: m/z calcd for C19H12NO2
 
[M+H]+: 286.0868; found 286.0829. 
 
4.2.30 7-Iodo-1-(naphthalen-2-ylmethyl)-1H-indole-2,3-dione (37) 
 
The compound was prepared according to the method for 
13 using 32 (2.50 g, 9.16 mmol), NaH (307 mg, 12.8 mmol), KI 
(304 mg, 1.83 mmol) and 2-(bromomethyl)naphthalene (3.03 g, 
13.7 mmol) as starting materials. The resulting solid was purified 
by flash chromatography (100% CHCl3) to yield 37 as red/brown 
crystals (1.37 g, 36%), m.p. 154-155 °C. 1H NMR (CDCl3, 
500 MHz): δ 5.64 (s, 2H), 6.88 (t, J = 7.5 Hz, 1H), 7.38 (d, 
J = 7.5 Hz, 1H), 7.46 (dd, J = 3.0 Hz, 6.0 Hz, 2H), 7.61 (s, 1H), 
7.68 (d, J = 6.5 Hz, 1H), 7.75 (dd, J = 3.0 Hz, 5.5 Hz, 1H), 
7.81-7.85 (m, 2H), 7.94 (d, J = 8.0 Hz, 1H). 13C NMR (CDCl3, 
126 MHz):  43.8, 73.7, 120.8, 124.4, 124.9, 125.5, 125.7, 126.0, 
126.4, 127.7, 127.8, 128.7, 132.7, 133.3,† 150.9, 151.1, 159.2, 
182.4. LREI-MS: m/z (%): 413 (56) [M+], 272 (85) [M-CH2C10H7], 
141 (100), 115 (47). HRESI-MS: m/z calcd for C19H13INO2 






The compound was prepared according to the method for 
34 using the isatin 37 (1.10 g, 2.66 mmol), ethylene glycol (4.95 g, 
4.45 mL, 79.8 mmol) and PTSA (110 mg, 10% of starting material 
weight) as starting materials. The resulting solid was purified by 
flash chromatography (100% DCM) to yield 38 as a beige powder 
(1.12 g, 92%), m.p. 156-158 °C.  1H NMR (CDCl3, 500 MHz): 
δ 4.36-4.39 (m, 2H), 4.62-4.64 (m, 2H), 5.51 (s, 2H), 6.82 (t, 
J = 8.0 Hz, 1H), 7.35 (dd, J = 1.5 Hz, 8.5 Hz, 1H), 7.41 (dd, 
J = 1.0 Hz, 7.0 Hz, 1H), 7.43-7.45 (m, 2H), 7.57 (s, 1H), 7.71 (dd, 
J = 1.0 Hz, 8.5 Hz, 1H), 7.75-7.77 (m, 1H), 7.80-7.82 (m, 2H). 
13C NMR (CDCl3, 126 MHz):  43.7, 66.3,
† 72.6, 101.1, 124.5, 
124.7, 124.9, 125.2, 125.7, 126.1, 127.4, 127.6, 127.9, 128.5, 
132.6, 133.4, 134.1, 144.4, 144.5, 174.5. LREI-MS: m/z (%): 457 
(23) [M+], 316 (100) [M-CH2C10H7], 272 (45) [M-CH2C10H7-
(CH2)2O], 141(37), 115 (35). HRESI-MS: m/z calcd for 
C21H17INO3 [M+H]





The compound was prepared according to the method for 
35 using the ketal 38 (1.00 g, 2.19 mmol), Pd(OAc)2 (49.2 mg, 
219 µmol), TBAB (777 mg, 2.41 mmol) and NaOAc (902 mg, 
11.0 mmol) as starting materials. The resulting solid was purified 
using flash chromatography (100% CHCl3) to yield 39 as a beige 
powder (485 mg, 67%), m.p. 161-163 °C. 1H NMR (CDCl3, 
500 MHz): δ 4.36 (t, J = 6.5 Hz, 2H), 4.61 (t, J = 6.5 Hz, 2H), 5.05 
(s, 2H), 7.14 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H), 7.30 (d, 
J = 7.5 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.56 (t, J = 7.5 Hz, 1H), 
7.74 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 9.0 Hz, 1H), 8.17 (d, 
J = 8.5 Hz, 1H), 8.63 (d, J = 9.0 Hz, 1H). 13C NMR (CDCl3, 
126 MHz):  44.5, 66.1,† 119.1, 121.6, 123.3, 124.1, 125.1, 125.3, 
125.5, 126.1, 127.3, 129.2, 129.3, 129.4, 129.8, 130.2, 134.4, 
141.9,†174.3. LREI-MS: m/z (%): 329 (44) [M+], 300 (100), 256 
(31), 229 (28), 201 (18), 128 (33), 114 (32), 100 (28). HRESI-MS: 
m/z calcd for C21H16NO3





The compound was prepared according to the method for 
36 using the cyclised ketal 39 (420 mg, 1.28 mmol) in 6 M 
HCl/THF (1:1, 13.4 mL) as starting materials to yield 40 as a fine 
dark red powder (330 mg, 90%), m.p. 205-207 °C. 1H NMR 
(CDCl3, 500 MHz): δ 5.15 (s, 2H), 7.18 (t, J = 8.0 Hz, 1H), 7.24 
(d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.55 (t, J = 8.5 Hz, 
1H), 7.60 (td, J = 1.0 Hz, 8.5 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 
7.89 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 8.55 (d, 
J = 8.5 Hz, 1H). 13C NMR (CDCl3, 126 MHz):  44.3, 117.2, 
120.2, 123.6, 123.9, 124.2, 124.6, 124.7, 126.3, 127.6, 129.2, 
129.8, 129.9, 130.8, 134.2, 135.6, 149.2, 158.8, 183.1. LREI-MS: 
m/z (%): 285 (48) [M+], 256 (100), 228 (35), 201 (26), 128 (13), 
114 (39), 100 (48). HRESI-MS: m/z calcd for C19H12NO2
 [M+H]+: 





According to the bromination method of 
Zysman-Colman et al.,35  the cyclised phenanthridine 40 (100 mg, 
351 µmol) was dissolved in anhydrous CH3CN (1 mL) at 0 °C. 
NBS (62.5 mg, 351 µmol) in anhydrous CH3CN (1 mL) was added 
and the reaction mixture was warmed to RT and stirred for 18 h. 
DCM (30 mL) was added and the solution was extracted with H2O 
(3 × 20 mL). The organic extract was dried over MgSO4, filtered 
and evaporated. The resulting solid was purified using flash 
chromatography (100% CHCl3) to yield 41 as a fine dark red 
powder (49.2 mg, 39%), m.p. 197-199 °C. 1H NMR (CDCl3, 
500 MHz): δ 5.09 (s, 2H), 7.20 (d, J = 8.0 Hz, 1H), 7.47-7.57 (m, 
2H), 7.63 (app. bs, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.87 (d, 
J = 7.0 Hz, 1H), 8.30-8.35 (m, 1H), 8.41 (bs, 1H). 13C NMR 
(CDCl3, 126 MHz):  44.2, 116.6, 118.1, 122.0, 122.7, 124.0, 
124.6, 126.1, 126.5, 128.1, 129.4, 129.6, 130.7, 134.1, 135.6, 
137.5, 147.9, 157.9, 181.7. LREI-MS: m/z (%): 363/365 (24) 
[M+]79Br/81Br, 334/336 (38), 256 (53), 227 (61), 200 (35), 100 
(65). HRESI-MS: m/z calcd for C19H11
79BrNO2
 [M+H]+: 363.9973; 
found 363.9991. 
 
4.3 Cytotoxicity Testing 
Human U937 histiocytic lymphoma cells were obtained 
from the American Type Culture Collection (ATCC, VA, USA). 
Cells were routinely maintained in RPMI-1640 medium, 
containing 2 mM L-glutamine, 5.6 % (2 g/L) sodium bicarbonate 
and 5 % fetal calf serum (at 37 °C, 95 % humidified atmosphere 
and 5 % CO2). Cytotoxicity of the isatin derivatives was 
determined using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS assay) (Promega Co., Madison, WI, 
USA) as described previously.1c The concentration required to 
inhibit 50 % of the metabolic activity of the cell population (IC50) 
was calculated from sigmoidal dose-response curves using 
GraphPad Prism 5.00 (GraphPad Software Inc., San Diego, CA, 
USA) from at least two independent experiments performed in 
triplicate.  
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